Re: Frans Debruyne, Arkadij A. Gres, Dmitrii L. Arustamov. Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist Cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 2008;54:170-80.
Drewa
Tomasz
T
Chlosta
Piotr
P
D000726:Androgen Antagonists / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000627:therapeutic use / Q000633:toxicity; D006727:Hormone Antagonists / Q000627:therapeutic use* / Q000633:toxicity; D006801:Humans; D008297:Male; D009929:Organ Size; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D013234:Stem Cells / Q000473:pathology
D000726:Androgen Antagonists; D006727:Hormone Antagonists; D007987:Gonadotropin-Releasing Hormone; C062876:cetrorelix